Literature DB >> 34796380

Immunosuppression in Lung Transplantation.

Joelle Nelson1,2,3, Elisabeth Kincaide1,2,3, Jamie Schulte4, Reed Hall1,2,3, Deborah Jo Levine5.   

Abstract

Immunosuppression in lung transplantation is an area devoid of robust clinical data. This chapter will review the history of immunosuppression in lung transplantation. Additionally, it will evaluate the three classes of induction, maintenance, and rescue immunosuppression in detail. Induction immunosuppression in lung transplantation aims to decrease incidence of lung allograft rejection, however infectious risk must be considered when determining if induction is appropriate and which agent is most favorable. Similar to other solid organ transplant patient populations, a multi-drug approach is commonly prescribed for maintenance immunosuppression to minimize single agent drug toxicities. Emphasis of this review is placed on key medication considerations including dosing, adverse effects, and drug interactions. Clinical considerations will be reviewed per drug class given available literature. Finally, acute cellular, antibody mediated, and chronic rejection are reviewed.
© 2021. Springer Nature Switzerland AG.

Entities:  

Keywords:  CLAD; Immunosuppression; Lung transplant

Mesh:

Substances:

Year:  2022        PMID: 34796380     DOI: 10.1007/164_2021_548

Source DB:  PubMed          Journal:  Handb Exp Pharmacol        ISSN: 0171-2004


  96 in total

1.  Four-hour versus 24-hour intravenous infusion of FK 506 in liver transplantation.

Authors:  K M Abu-Elmagd; J Fung; R Draviam; W Shannon; A Jain; M Alessiani; S Takaya; R Venkataramanan; V S Warty; A Tzakis
Journal:  Transplant Proc       Date:  1991-12       Impact factor: 1.066

Review 2.  Post-transplant dyslipidemia: Mechanisms, diagnosis and management.

Authors:  Arnav Agarwal; G V Ramesh Prasad
Journal:  World J Transplant       Date:  2016-03-24

Review 3.  Enteric-coated mycophenolate sodium: tolerability profile compared with mycophenolate mofetil.

Authors:  Matthias Behrend; Felix Braun
Journal:  Drugs       Date:  2005       Impact factor: 9.546

4.  Comparison of sirolimus with azathioprine in a tacrolimus-based immunosuppressive regimen in lung transplantation.

Authors:  Sangeeta Bhorade; Vivek N Ahya; Maher A Baz; Vincent G Valentine; Selim M Arcasoy; Robert B Love; Harish Seethamraju; Charles G Alex; Remzi Bag; Nilto C Deoliveira; Aliya Husain; Wickii T Vigneswaran; Jeff Charbeneau; Jerry A Krishnan; Ramon Durazo-Arvizu; Lourdes Norwick; Edward Garrity
Journal:  Am J Respir Crit Care Med       Date:  2010-09-10       Impact factor: 21.405

5.  Effect of low- and high-fat meals on tacrolimus absorption following 5 mg single oral doses to healthy human subjects.

Authors:  I Bekersky; D Dressler; Q A Mekki
Journal:  J Clin Pharmacol       Date:  2001-02       Impact factor: 3.126

6.  Steroid withdrawal in lung transplant recipients.

Authors:  J M Borro; A Solé; M De la Torre; A Pastor; V Tarazona
Journal:  Transplant Proc       Date:  2005-11       Impact factor: 1.066

7.  Comparative study of basiliximab treatment in lung transplantation.

Authors:  J M Borro; M De la Torre; C Míguelez; R Fernandez; D Gonzalez; C Lemos
Journal:  Transplant Proc       Date:  2005-11       Impact factor: 1.066

Review 8.  Pharmacologic immunosuppression.

Authors:  Neal R Barshes; Sarah E Goodpastor; John A Goss
Journal:  Front Biosci       Date:  2004-01-01

9.  Outcome of Extracorporeal Photopheresis as an Add-On Therapy for Antibody-Mediated Rejection in Lung Transplant Recipients.

Authors:  Alberto Benazzo; Nina Worel; Stefan Schwarz; Ulrike Just; Anna Nechay; Christoph Lambers; Georg Böhmig; Gottfried Fischer; Daniela Koren; Gabriela Muraközy; Robert Knobler; Walter Klepetko; Konrad Hoetzenecker; Peter Jaksch
Journal:  Transfus Med Hemother       Date:  2020-05-05       Impact factor: 3.747

Review 10.  Antibody-mediated rejection after lung transplantation.

Authors:  Amit I Bery; Ramsey R Hachem
Journal:  Ann Transl Med       Date:  2020-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.